Supplementary Materials and Methods, Supplementary Tables 1 through 3, and Supplementary Figures 1 through 8 from Tunicamycin Potentiates Cisplatin Anticancer Efficacy through the DPAGT1/Akt/ABCG2 Pathway in Mouse Xenograft Models of Human Hepatocellular Carcinoma

Authors:
Open Access
Publisher website
Google Scholar
Abstract
PDF - 922KB, Supplementary Materials and Methods. Supplementary Table S1: Drugs and chemical reagents. Supplementary Table S2: Primers used for Real-time PCR and other sequences. Supplementary Table S3: Antibodies used in this study. Supplementary Figure S1. The expression of ABCG2 was correlated with drug resistance of HCC. Supplementary Figure S2. TM inhibited ABCG2 expression in both HCC and other tumor cell lines. Supplementary Figure S3. Glycosylation inhibitors influenced SP of HCC cells. Supplementary Fig. S4 TM inhibited ABCG2 and p-Akt expression in CD133+/- MHCC-97L cells nude mouse models. Supplementary Figure S5. The anti-tumor effect of chemotherapeutic drugs combined with TM in PLC/PRF/5 cells was evaluated by Western blotting. Supplementary Figure S6. TM enhanced the therapeutic effect of CDDP through Akt-ABCG2 pathway in vivo. Supplementary Figure S6. TM inhibited the glycosylation of EGFR and blocked its downstream signalling. Supplementary Figure S8. The combination treatment effect of sorafenib and TM was evaluated in HCC cell lines.